Before the opening bell, Immune Therapeutics, Inc. (OTCQB:
IMUN) announced the appointment of two new members to its board of directors:
Dr. Clifford A. Selsky and Paul Akin. Akin brings a wealth of financial
experience developed across his prior operating and board roles to the Immune
Therapeutics board, while Selsky offers a critical perspective as a scientist,
physician and patient advocate. The company will look to leverage this combined
experience as it continues to pursue sustainable financial growth by developing
and commercializing novel, patented therapies to combat chronic,
life-threatening diseases through the activation and modulation of the body’s
immune system, particularly in emerging global markets.
“Paul Akin and Dr. Selsky’s breadth of knowledge and
experience will provide invaluable insight to Immune as we continue to grow the
business and strive to deliver innovative therapies in emerging nations,”
Noreen Griffin, chief executive officer of Immune Therapeutics, stated in this
morning’s news release.
The release went on to provide additional background
information on the company’s new board members.
Paul Akin brings more than 25 years of leadership experience
to the Immune Therapeutics board. In addition to serving as a significant
investor and active strategist for the company, he has played an instrumental
role in the strategic planning and coordination of market penetration,
expansion and capitalization. Akin currently serves as the CEO and executive
chairman of San Francisco-based Collier Warehouse Group, which has, during his
tenure, recorded annual double-digit growth rates. Akin is also an active
investor in a variety of emerging growth companies and has served in a number
of business roles – including executive chairman, independent board director,
strategic advisor, venture capital limited partner, market pundit, private
investor and trustee.
Clifford A. Selsky, PhD, MD, has worked as a practicing
pediatrician for the past 20 years. He earned his PhD in microbiology and
molecular genetics at the University of Miami School of Medicine before
completing DNA repair research studies at Harvard School of Public Health and
Stanford University. After training in pediatrics at Yale New Haven Hospital
and completing a pediatric hematology and oncology fellowship at Yale
University School of Medicine, Selsky founded the Children’s Center of Cancer
and Blood Disease at the Florida Hospital Cancer Institute. Currently, he is a
pediatrician at Family First Pediatrics, which he established in 2013.
Immune Therapeutics, Inc. is a biotechnology company with a
promising portfolio of products and immunotherapy technologies designed to
harness the power of the immune system in order to enhance the treatment of
cancer, infections such as HIV/Aids, chronic inflammatory diseases and
autoimmune diseases. The company is currently pursuing investigations of its
most advanced clinical programs – including met-enkephalin (MENK) and low dose
naltrexone (LDN), or Lodonal™ – as viable treatments for a variety of underserved
indications.
Learn more by visiting www.immunetherapeutics.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment